Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)
On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock.
Centessa Pharmaceuticals Plc (CNTA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 14,555,555 | $364,034,431 | +35% | 3.58% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 11,281,741 | $282,156,342 | +13% | 0.43% |
| 3. | Farallon Capital Thomas Steyer | 5,377,068 | $134,480,471 | +25% | 0.63% |
| 4. | Siren L.L.C. Raymond Debbane | 4,027,517 | $100,728,200 | +25% | 3% |
| 5. | EcoR1 Capital Oleg Nodelman | 3,115,000 | $77,906,150 | +467% | 3.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.73 | 417,646 | $5,315,004.76 | 462,585 | 2025-05-16 | Filing | |
| $12.24 | 44,939 | $550,237.61 | 44,939 | 2025-05-15 | Filing | |
| $4.63 | 10,000 | $46,284.00 | 38,000 | 2022-06-24 | Filing | |
| $9.74 | 5,000 | $48,700.00 | 28,000 | 2022-02-02 | Filing | |
| $9.05 | 27,500 | $248,754.00 | 27,500 | 2022-01-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.15 | 38,951 | $979,656.60 | 57,645 | 2026-02-02 | Filing | |
| $25.01 | 1,010 | $25,261.01 | 104,376 | 2026-01-30 | Filing | |
| $29.21 | 2,568 | $75,005.37 | 178,801 | 2025-12-09 | Filing | |
| $28.70 | 7,432 | $213,283.54 | 181,369 | 2025-12-09 | Filing | |
| $30.00 | 10,000 | $300,000.00 | 188,801 | 2025-12-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,963,157 | $499,278,557 | 59.8% | |
| 2. | 9,961,789 | $249,144,343 | 100% | |
| 3. | 8,961,939 | $224,138,094 | 0.01% | |
| 4. | 6,117,715 | $153,004,052 | 5.33% | |
| 5. | 4,286,480 | $107,204,865 | 3.55% |
News See All
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the promising stocks to buy under $50.
10 Promising Stocks to Buy Under $50
On January 7, Jay Woods, Chief Market Strategist at Freedom Capital Markets, joined CNBC to state that stocks are broadening beyond tech, with materials, defense, transports, and airlines showing breakouts...
Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks to buy according to Wall Street.
10 Best Up and Coming Stocks to Buy According to Wall Street
On December 26, Thomson Nguyen, Saga Ventures co-founder and managing partner, joined 'Squawk Box' on CNBC to discuss the resurgence of the IPO market following a strong 2025 performance.
Analysts Boost Centessa Pharmaceuticals plc (CNTA) Price Targets as Sleep Disorder Drug Shows Breakthrough Results
Centessa Pharmaceuticals plc (NASDAQ:CNTA) is one of the best 52-week high stocks to buy right now. On December 1, B.
12 Best 52-Week High Stocks to Buy Right Now
All three major US indices are poised to end the year near record highs in what is turning out to be a blockbuster year for stocks.
Centessa (CNTA) Hits All-Time High on New $287-Million Fundraising Program
In a statement, Centessa Pharmaceuticals plc (NASDAQ:CNTA) said it plans to issue more than 11.6 million new American depositary shares (ADS) at a price of $21.50 apiece.
LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential.
Hedge Fund Resource Center